Cytomegalovirus prophylaxis in solid organ transplantation

Area of Science:

• Virology
• Immunology
• Transplantation Medicine

Background:

• Human Cytomegalovirus (CMV) establishes lifelong latent infections in most adults.
• Effective control of CMV relies on a coordinated innate and adaptive immune response, particularly cellular immunity (CD4+ and CD8+ T cells).
• Solid organ transplant recipients are highly susceptible to CMV disease due to immunosuppression, especially those undergoing T cell-depleting therapies.

Purpose of the Study:

• To review the impact of CMV in solid organ transplantation.
• To discuss current strategies for CMV prophylaxis and the controversy surrounding therapy duration.
• To highlight the potential for immune response assays to personalize CMV treatment.

Main Methods:

• Literature review of CMV pathogenesis, immunology, and clinical management in transplant recipients.
• Analysis of current guidelines and controversies regarding antiviral prophylaxis duration.
• Exploration of the role of immune monitoring in future therapeutic strategies.

Main Results:

• CMV infection causes significant morbidity and mortality in transplant recipients through direct viral effects and immune modulation.
• Antiviral nucleoside analogue prophylaxis is standard but optimal duration is debated.
• Assaying individual immune responses to CMV holds promise for tailoring therapy.

Conclusions:

• CMV poses a substantial threat to solid organ transplant recipients.
• Personalized prophylaxis duration based on immune status could optimize patient outcomes.
• Further research into immune assays is warranted to guide clinical practice.